Lantheus Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $388.20M | $1.11 | $1.55 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $377.30M | $1.80 | $1.46 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $406.80M | $0.82 | $1.67 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $384.00M | $0.41 | $1.27 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $378.00M | $1.12 | $1.57 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $372.80M | $1.02 | $1.53 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | $391.10M | $-0.17 | $1.59 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $378.70M | $1.79 | $1.70 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| FY 2026 Adjusted fully diluted EPSnon-GAAP | FY 2026 | $5.00 to $5.25 | Maintained |
| FY 2026 Revenue | FY 2026 | $1.40B to $1.45B | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Lantheus filed with the SEC
Lantheus Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Curium Announces Definitive Agreement to Merge with Lantheus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Curium Combined company would span full radiopharmaceutical value chain delivering nuclear medicine solutions to patients and healthcare systems across more than 70 countries August 3, 2026 © 2026 Lantheus. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Announces Leadership Transition Plan
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Lantheus Completes Acquisition of Evergreen Theragnostics
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance
Results of operations · EX-99.1 to Form 8-K
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Lantheus. All rights
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Lantheus. All rights
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Lantheus Announces Share Repurchase Program
Other events · EX-99.1 to Form 8-K
Lantheus Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Acquires Global Rights to Life Molecular Imagings Novel Therapeutic and Diagnostic Pair
Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Lantheus Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Announces Acquisition of Cerveau Technologies, Inc.,
Regulation FD disclosure · EX-99.1 to Form 8-K
41st Annual J.P. Morgan Healthcare
Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
Other events · EX-99.1 to Form 8-K
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
Lantheus Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Lantheus 2022 Investor Day May 17 | New
Regulation FD disclosure · EX-99.1 to Form 8-K
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K